Olaparib first became FDA-approved in December 2014 for patients with advanced ovarian cancer positive for BRCA mutations, becoming the first PARP inhibitor to be FDA-approved following the clinical trial Study 19 (NCT00753545) (22). Here, PARP1 is linked to ovarian carcinoma.